ChromaDex® Reports Financial Results for the Third Quarter 2012

IRVINE, Calif., Nov. 8, 2012 /PRNewswire/ -- ChromaDex(®) Corporation (OTCQB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure(®), announced today financial results for the third quarter ended September 29, 2012.

(Logo: http://photos.prnewswire.com/prnh/20110830/LA59283LOGO)

For the three months ended September 29, 2012, ChromaDex reported record revenue of $3,632,244, an increase of 99% as compared to $1,827,568 for the same period in 2011. The increase in sales is largely due to an increase in sales of the Company's BluScience(TM) line of dietary supplements. The net loss attributable to common stockholders for the quarter ended September 29, 2012 was $1,538,034, or ($0.02) per share as compared to a net loss of $2,404,912, or ($0.03) per share for the same period in 2011. The non-cash, share-based compensation expense related to stock options and other share-based compensation for the third quarter of 2012 was $925,393. Excluding non-cash, share-based compensation expense, which is a "non-GAAP measure," would have the effect of decreasing the Company's net loss for the third quarter of 2012 to $612,641. As of September 29, 2012, cash, cash equivalents and marketable securities totaled approximately $1.2 million and inventories totaled approximately $5.4 million.

Third quarter highlights include: